PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner

PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner

Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer and effective treatment regimens are yet to be established. Tyrosine kinase inhibitors (TKI) have widely been used as ccRCC therapeutics, but their efficacy is limited due to accompanying resistance mechanisms. Previous...

Full description

Bibliographic Details
Main Authors: Minghua Cao, Karol Nawalaniec, Amrendra K. Ajay, Yueming Luo, Romana Moench, Yanfei Jin, Sheng Xiao, Li-Li Hsiao, Ana Maria Waaga-Gasser
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Translational Oncology
Subjects:
Phosphodiesterase 4D
cAMP
Renal cell carcinoma
Tyrosine kinase inhibitor
MAPK/ERK pathway
CRAF
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523322000390

Similar Items

Similar Items